From Genomic Insight to Clinical Impact: Dramatic Response in RET Fusion–positive Pancreatic Cancer
Anticancer Research · 2026
DOI: 10.21873/anticanres.18417 ↗Kurz gefasst
Fallbericht in der Zeitschrift Anticancer Research, 2026. Verfasst von Jessica Lucchetti und 8 weiteren Autor:innen. Beteiligte Einrichtung: Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy; jess.lucchetti@gmail.com. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-ret, Pancreatic Neoplasms, Oncogene Proteins, Fusion, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND/AIM: Pancreatic cancer remains one of the deadliest solid malignancies despite advances in systemic treatment. Outcomes with current therapies remain modest, with a 5-year overall survival rate of no more than 20%. Although rare, oncogenic RET fusions represent a clinically actionable alteration and may predict substantial benefit from selective RET inhibition. CASE REPORT: A 48-year-old woman with pancreatic ductal adenocarcinoma developed liver metastases after first-line modified FOLFIRINOX. Comprehensive genomic profiling of the initial biopsy identified an NCOA4-RET fusion involving NCOA4 exon 6 and RET exon 12. Selpercatinib was initiated through a compassionate-use program at 160 mg twice daily. After approximately three months, the patient achieved a reduction of more than 50% in the sum of target-lesion diameters according to RECIST version 1.1. The response was sustained for more than 12 months despite dose reduction for persistent grade 2 hypertransaminasemia. The most recent assessment showed continued regression, including complete disappearance of some liver metastases. The patient remains clinically well, with an ECOG performance status of 0 and ongoing treatment. CONCLUSION: This case demonstrates the potential for durable and clinically meaningful responses to RET-targeted therapy in RET fusion-positive pancreatic cancer. It also supports the use of comprehensive genomic profiling to identify rare but actionable molecular alterations in patients with advanced pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy; jess.lucchetti@gmail.com.
- Operative Research Unit of Radiology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
- Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
- Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy.
Zitieren
APA
Lucchetti, J., Cimini, P., Angotti, L., Barnini, G., DI Giacomo, E., Muscio, L. G., Nitti, D., Vincenzi, B., & Tonini, G. (2026). From Genomic Insight to Clinical Impact: Dramatic Response in RET Fusion–positive Pancreatic Cancer. Anticancer Research. https://doi.org/10.21873/anticanres.18417
Vancouver
Lucchetti J, Cimini P, Angotti L, Barnini G, DI Giacomo E, Muscio LG, et al. From Genomic Insight to Clinical Impact: Dramatic Response in RET Fusion–positive Pancreatic Cancer. Anticancer Research. 2026. doi:10.21873/anticanres.18417
BibTeX
@article{Lucchetti2026,
author = {Lucchetti, Jessica and Cimini, Paola and Angotti, Lorenzo and Barnini, Giulia and DI Giacomo, Emanuela and Muscio, Luca Galbato and Nitti, Daniele and Vincenzi, Bruno and Tonini, Giuseppe},
title = {From Genomic Insight to Clinical Impact: Dramatic Response in RET Fusion–positive Pancreatic Cancer},
journal = {Anticancer Research},
year = {2026},
doi = {10.21873/anticanres.18417}
}
EUVIMED